Mati Therapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
101 Colorado St Apt 2409, Austin, Texas,...Phone Number
(512) 720-1333Website
www.matitherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Mati Therapeutics
Mati Therapeutics, based in Austin, Texas, specializes in developing a non-invasive sustained drug delivery platform aimed at treating ocular diseases, particularly glaucoma. The company has created the Evolute Punctal Plug Delivery System, a discreet device that automatically administers medication over an extended period, alleviating the need for patients or caregivers to use eye drops. With a leadership team boasting over a century of combined experience in ophthalmology, Mati is committed to enhancing treatment outcomes for patients with ocular disorders. Their innovative approach addresses the significant global issue of vision impairment, which affects over 1 billion people worldwide.Explore more
Mati Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mati Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Mati Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Mati Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Mati Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Mati Therapeutics launches new products
Earning: See what the market has to say on Mati Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Mati Therapeutics
Check out if Mati Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Mati Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Mati Therapeutics
Find 2 more new buyers
Compare Similar Companies to Mati Therapeutics
Compare insights from companies similar to Mati Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mati Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mati Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mati Therapeutics.
Mati Therapeutics financials insights
Gather financial insights about Mati Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$1.3M
2025
Private Equity
$2.2M
Private Equity
$9.9M
Mati Therapeutics Tech Stack
A closer look at the technologies used by Mati Therapeutics
Most Recent Scoops
Funding
Funding
Funding
Funding
Promotion
Executive Move
Promotion
Executive Move
Mati Therapeutics News & Media
MATI THERAPEUTICS ANNOUNCES COMPLETION OF MANUFACTURING FACILITY DEDICATED TO GLOBAL PRODUCTION OF ALL PUNCTAL PLUG DELIVERY SYSTEM (PPDS) PRODUCTS
Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all...Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made inJCRS Publication of Phase II Nepafenac Clinical Trial With Evolute® Sustained Drug Delivery System Demonstrates Significant Post-Op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that a peer reviewed manuscript of a Phase II clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute® sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery. The trial is a multi-center, randomized, masked evaluation of Nepafenac vs. placebo in 56 patients undergoing cataract surgery. The primary endpoint was toMati Therapeutics Announces Purchase of Rights From Novelion Therapeutics Inc.
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that it has purchased all rights related to Mati’s Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics Inc. (“Novelion”). This purchase is part of Novelion’s voluntary liquidation process. Mati previously acquired the intellectual property and other assets comprising the PPDS from Novelion (formerly QLT Inc.) in April 2013. As part of the purchase agreement, Mati was obligated to potentially pay Novelio
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mati Therapeutics
Sign Up For FreeTo access detailed company insights
Mati Therapeutics, based in Austin, Texas, specializes in developing a non-invasive sustained drug delivery platform aimed at treating ocular diseases, particularly glaucoma. The company has created the Evolute Punctal Plug Delivery System, a discreet device that automatically administers medication over an extended period, alleviating the need for... Read More
